MARKET WIRE NEWS

Subscribe to Our Newsletter

New study from CVS Caremark and Employee Benefit News shows how employers rely on their pharmacy benefit manager to create sustainable pharmacy solutions

MWN-AI** Summary

A recent study from CVS Caremark, conducted in collaboration with Employee Benefit News, highlights the growing reliance of employers on Pharmacy Benefit Managers (PBMs) to navigate escalating drug prices and enhance access to quality care. The findings from "The State of Pharmacy Management Survey" indicate that a significant 91% of employers are concerned about the rising costs of medications for their employees. In fact, 88% perceive PBMs as well-positioned to mitigate these costs, with 64% believing they have the potential to improve access to affordable specialty medications.

Key opportunities for employers lie in promoting the use of biosimilars and managing expensive treatments like GLP-1s. The survey reveals that while 49% of employers encourage biosimilar substitution, only 12% are educating employees on the cost-saving potential of these alternatives. CVS Caremark's initiatives in promoting biosimilar adoption have already resulted in over $3.3 billion in savings related to the drug Humira.

Furthermore, in light of the rising demand for GLP-1 weight management medications, 77% of employers express concern about the associated costs. CVS Caremark aims to address affordability by negotiating better prices and providing tailored management strategies, yielding significant savings for clients.

Digital innovation also plays a crucial role in modern pharmacy benefits, with 88% of employers agreeing that technological tools are essential for enhancing member experiences. CVS Caremark invests substantially in technology to optimize accessibility and personalization for plan members.

Ultimately, with only 30% of employers feeling they have significant control over pharmacy costs, CVS Caremark seeks to provide transparency, predictability, and sustainability in drug pricing, addressing employer concerns and improving member access to quality treatment.

MWN-AI** Analysis

The recent study by CVS Caremark, in collaboration with Employee Benefit News, highlights a growing reliance among employers on Pharmacy Benefit Managers (PBMs) to manage the escalating costs of prescription drugs and enhance employee health care access. With 91% of employers expressing concern over medication costs, the findings indicate a critical point of intervention for businesses seeking sustainable pharmacy solutions.

Notably, the survey reveals that 88% of employers view PBMs as well-positioned to mitigate pharmaceutical expenses. This trend provides an opportunity for companies to leverage the expertise of PBMs in negotiating prices and promoting cost-effective alternatives, particularly biosimilars. Currently, only 49% of employers encourage biosimilar use, suggesting a substantial gap in awareness and implementation. Companies should prioritize educating their workforce about the advantages of these lower-cost medications, which have already yielded over $3.3 billion in savings for CVS Caremark clients.

Additionally, the report underscores the increasing significance of managing GLP-1 treatments as weight management gains traction in employee benefits. With 77% of employers concerned about the costs associated with GLP-1 drugs, implementing comprehensive management programs can alleviate financial burdens while fostering employee well-being. CVS Caremark's focus on personalized support has demonstrated success, leading to a 26% reduction in spending for employers who adopted their Weight Management program.

As digital innovation reshapes health care, employers must seek PBMs that integrate advanced technology to enhance the member experience. With 88% of surveyed employers emphasizing the importance of digital tools, aligning with PBMs that invest in this area will ultimately drive better health outcomes and cost efficiencies.

In conclusion, to create sustainable pharmacy solutions, employers should actively engage with their PBMs to embrace biosimilars, manage specialty medications, and harness digital innovations—strategies that will not only control costs but also improve employee health outcomes.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: PR Newswire

PR Newswire

Key opportunities include: managing GLP-1s, encouraging biosimilar substitution and employing technology to simplify and personalize the member experience

WOONSOCKET, R.I., Aug. 12, 2026 /PRNewswire/ -- CVS Caremark, part of CVS Health® (NYSE: CVS), today announced the findings of a survey conducted in partnership with Employee Benefit News that reveals why employers are increasingly relying on their pharmacy benefit manager (PBM) partners to use their expertise, scale and purchasing power to help them manage their top concern: battling rising drug prices and maintaining access to quality care.

This year's The State of Pharmacy Management Survey findings show HR decision makers and executive leaders are focused on navigating the rising price of prescription drugs, managing access to expensive treatments such as GLP-1s, and encouraging the use of more cost-effective biosimilars.

Key Findings

  • 91% of employers are concerned about the high prices of medication for employees
  • 88% of employers see PBMs as especially well positioned to reduce prescription drug costs for their businesses
  • 64% say PBMs have the greatest opportunity to improve access to affordable specialty medications

"This data reveals the urgency behind employers' need for PBM partners who can address cost, first and foremost," said Ed DeVaney, President, CVS Caremark. "There's a clear opportunity to help employers navigate the evolving pharmacy benefits landscape while driving sustainable benefits for clients and members."

Opportunity for employers to encourage greater use of biosimilars
The survey findings also illustrate that biosimilars represent one of the largest untapped opportunities for employers to reduce drug costs in the U.S. health care market, offering clinically equivalent therapies to improve affordability and enhance access without compromising safety or efficacy.

Today, only about half of employers (49%) are encouraging biosimilar substitution while another 40% are actively considering or exploring it. With just 12% of employers reporting that they are educating employees about the cost savings potential, this study illustrates a significant opportunity for employers to do more to both create better awareness and understanding of the benefits of biosimilars and help their members access them.

CVS Caremark has been an industry leader in promoting biosimilar adoption. Since April 2024, biosimilar formulary strategy has helped CVS Caremark clients and members realize more than $3.3 billion in gross savings related to Humira® (adalimumab), and the company is committed to expanding the use of low-cost biosimilars across multiple therapeutic categories.

On July 1, 2026, CVS Caremark transitioned from Stelara® (ustekinumab) on its most common commercial template formularies to prefer lower-cost, interchangeable biosimilar alternatives — Pyzchiva® and Yesintek®. Most members will pay $0 out-of-pocket for their therapy.

Employers are planning for emerging areas of pharmacy spend, including GLP-1 weight management
Weight management has moved into the benefits mainstream, becoming a core component of modern benefits strategy. Seventy-seven percent of employers say the high cost of GLP-1 coverage is a concern — with 80% having either already limited GLP-1 coverage for weight loss or considering limits.

CVS Caremark is focused on improving affordability and access to GLP-1s by increasing access to GLP-1 weight management medications this year with expanded coverage options. In addition to negotiating lower prices with drug manufacturers, CVS Caremark works with clients to leverage the right GLP-1 management strategies for each employee population, including utilization management, personalized clinical and nutrition support and more. 

The lifestyle-first approach of the CVS Weight Management™ program has driven sustainable weight loss results for members and cost savings for plan sponsors. Clients who adopted the program spent up to 26% less on GLP-1 medications for weight-loss compared to those who did not, and members who were previously on anti-obesity medication nearly doubled their pre-program weight loss while working with program clinicians on diet and lifestyle.

Digital innovation is central to pharmacy benefits
As AI and digital enablement continue to transform the health care experience, employers are looking for pharmacy benefits partners who can leverage digital tools to make support more accessible, personalized and navigable for plan members, with 88% saying that digital tools and innovation as part of the health care experience are "here to stay."

CVS Caremark invests over $770 million in technology each year dedicated to member innovation, combining human touch with streamlined digital processes so members can receive the treatment they need quickly. As a founding partner of the Coalition for Health AI (CHAI), CVS Caremark is also helping lead the way in safe and ethical use of AI in health care, all in support of improved health outcomes and a streamlined experience for members, clients and providers.

Employers see pharmacy benefit costs as harder to control than other benefits
Only 30% of employers said they have significant influence over pharmacy costs, compared to 73% who said they have significant influence over the overall cost of maintaining a competitive benefits package. At the same time, employers are looking for PBMs to help manage pharmacy spending while maintaining access to affordable treatment options. Of those surveyed, 91% say they are very concerned about high medication costs for employees.

CVS Caremark helps employers control drug costs and make medications more accessible by working with drug manufacturers to negotiate affordable drug prices for clients and members. Through the industry-leading pricing model, TrueCost™, CVS Caremark allows clients to see true drug costs through acquisition-cost-based pricing and drug-level rebate values, enabling more pricing transparency, predictability and sustainability for plan administrators and members and improving affordability for high-quality treatment.

View The State of Pharmacy Management report.

About CVS Health
CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of June 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Media contact
Phil Blando
202-258-4978
Phillip.Blando@CVSHealth.com

SOURCE CVS Health

FAQ**

How does CVS Health Corporation CVS plan to further utilize its purchasing power and expertise as a pharmacy benefit manager to help employers combat rising drug prices and improve access to affordable medications?
CVS Health Corporation plans to leverage its purchasing power and pharmacy benefit management expertise by negotiating better drug pricing, enhancing formulary management, and implementing cost-saving programs to help employers reduce expenses and improve access to affordable medications.
What specific initiatives is CVS Health Corporation CVS implementing to encourage greater adoption of biosimilars among employers, given the current low percentage of employers actively promoting this option?
CVS Health Corporation is implementing targeted educational campaigns, partnerships with employers to facilitate biosimilar adoption, and incentive programs for pharmacy benefits managers to encourage the use of biosimilars and improve patient access.
With 91% of employers concerned about high medication costs, how does CVS Health Corporation CVS intend to enhance its TrueCost™ model to provide more transparency and sustainability in pharmacy benefit management?
CVS Health Corporation aims to enhance its TrueCost™ model by leveraging data analytics to provide clearer insights into medication pricing and utilization, promoting cost-effective choices for employers, while ensuring sustainability in pharmacy benefit management.
In light of the significant reliance on digital tools indicated by employers, what innovative digital strategies is CVS Health Corporation CVS pursuing to streamline the pharmacy benefits experience for both members and employers?
CVS Health Corporation is leveraging innovative digital strategies such as integrated mobile apps, telehealth services, and advanced data analytics to enhance user experience, simplify pharmacy benefits, and improve accessibility for both members and employers.

**MWN-AI FAQ is based on asking OpenAI questions about CVS Health Corporation (NYSE: CVS).

CVS Health Corporation

NASDAQ: CVS

CVS Trading

0.24% G/L:

$89.64 Last:

7,437,163 Volume:

$90.16 Open:

iqst Ad 300

CVS Latest News

$95,397,851,248
1,255,468,728
N/A
1076
N/A
Medical Service Plans
Healthcare
US
Woonsocket

Check Your Online Brokerage For CVS

Link Market Wire News to Your X Account

Download The Market Wire News App

Schedule a 30 minute Brand Awareness meeting with Market Wire News